2206 J ournal of Medicinal Chemistry, 1996, Vol. 39, No. 11
Almansa et al.
(15) Dhanoa, D. S.; Bagley, S. W.; Chang, R. S. L.; Lotti, V. J .; Chen,
T.; Kivlighn, S. D.; Zingaro, G. J .; Siegl, P. K. S.; Patchett, A.
A.; Greenlee, W. J . Nonpeptide Angiotensin II Receptor Antago-
nists. 2. Design, Synthesis, and Biological Activity of N-Substi-
tuted (Phenylamino)phenylacetic Acids and Acyl Sulfonamides.
J . Med. Chem. 1993, 36, 4239-4249.
(16) (a) Dhanoa, D. S.; Bagley, S. W.; Chang, R. S. L.; Lotti, V. J .;
Chen, T.; Kivlighn, S. D.; Zingaro, G. J .; Siegl, P. K. S.;
Chakravarty, P. K.; Patchett, A. A.; Greenlee, W. J . (Dipropyl-
phenoxy)phenylacetic Acids: A New Generation of Nonpeptide
Angiotensin II Receptor Antagonists. J . Med. Chem. 1993, 36,
3738-3742. (b) Fitch, K. J .; Walsh, T. F.; Patchett, A. A.; Chang,
R. S. L.; Siegl, P. K. S.; Faust, K. A.; Chen, T.; Lotti, V. J .;
Kivlighn, S. D.; Zingaro, G. J .; Greenlee, W. J . AT1 Selective
Angiotensin II Antagonists with Phenoxyphenylacetic Acid as
Biphenyl Replacement Part I. Bioorg. Med. Chem. Lett. 1995,
5, 155-158.
(17) Taken in part from the following patent: Almansa, C.; Carceller,
E.; Gonza´lez, C.; Torres, C.; Bartrol´ı, J . New Imidazopyridine
Derivatives as Angiotensin II Antagonists. European Patent EP
669333, 1995.
(18) Batkowski, T.; Tomasik, D.; Tomasik, P. On the Synthesis of
3,5-dinitro-2,4-lutidine. Rocz. Chem. 1969, 43, 481-487.
(19) Feit, B. A.; Melamed, U.; Schmidt, R. R.; Speer, H. Vinyl Anions.
Part 9. Vinyl Carbanions Derived from Acrylic Esters and their
â-Phenyl Derivatives. J . Chem. Soc. Perkin Trans. 1981, 1329-
1338.
(20) El-Kholy, I. E.-S.; Rafla, F. K.; Mishrikey, M. M. Pyrone Series.
X. Reactivity of 4,5,6-Triaryl-2-pyrones and the Corresponding
Thio-analogs. J . Chem. Soc. 1969, 1950.
(21) Rhodes, R. A.; Boykin, D. W. The Selective Reduction of R,â-
Unsaturated Nitriles with Sodium Borohydride in Methanolic
Pyridine. Synth. Commun. 1988, 18, 681-687.
(22) Allen, C. F. H.; Spangler, F. W. Ethyl benzalmalonate. Organic
Syntheses; Wiley: New York, 1955; Coll. Vol. No. III, pp 377-
379.
(23) Newman, M. S.; Blum, J . The Synthesis and Ionization Con-
stants of the Six Hydroxybenzo[c]phenanthrenes. J . Am. Chem.
Soc. 1964, 86, 503-507.
the GC and HPLC analysis and to Dr. C. K. Prout,
Chemical Crystallography Laboratory, Oxford, for pro-
viding us with X-ray data.
Su p p or tin g In for m a tion Ava ila ble: X-ray crystallo-
graphic data, including positional parameters, bond distances,
bond angles, and anisotropic displacement parameter expres-
sions, for (-)-36g (16 pages). Ordering information is given
on any current masthead page.
Refer en ces
(1) Ferrario, C. M. The Renin-Angiotensin System: Importance in
Physiology and Pathology. J . Cardiovasc. Pharmacol. 1990, 15
(Suppl. 3), 51-55.
(2) Vallotton, M. B. The Renin-Angiotensin System. Trends Phar-
macol. Sci. 1987, 8, 69.
(3) Berecek, K. H.; King, S. J .; Wu, J . N. Angiotensin-Converting
Enzyme and Converting Enzyme Inhibitors. Cellular and Mo-
lecular Biology of the Renin-Angiotensin System; CRC Press:
Boca Raton, FL, 1993; pp 183-220.
(4) (a) Clozel, J . P.; Fischli, W. Discovery of Remikiren as the First
Orally Active Renin Inhibitor. Arzneim.-Forsch. 1993, 43, 260-
262. (b) Rosenberg, J . H.; Spina, K. P.; Condon, S. L.; Polakowski,
J .; Yao, Z.; Kovar, K.; Stein, H. H.; Cohen, J .; Barlow, J . L.;
Klinghofer, V.; Egan, D. A.; Tricarico, K. A.; Perun, T. J .; Baker,
W. R.; Kleiwert, H. D. Studies Directed Toward the Design of
Orally Active Renin Inhibitors. 2. Development of the Effica-
cious, Bioavailable Renin Inhibitor (2S)-2-Benzyl-3-[[(1-methyl-
piperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine Amide
of (2S, 3R, 4S)-2-Amino-1-cyclohexyl-3,3-dihydroxy-6-methyl-
heptane (A-72517). J . Med. Chem. 1993, 36, 460. (c) Kleinert,
H. D. Recent Developments in Renin Inhibitors. Exp. Opin.
Invest. Drugs 1994, 3, 1087-1104.
(5) (a) McEwan, J . R.; Fuller, R. W. Angiotensin Converting Enzyme
Inhibitors and Cough. J . Cardiovasc. Pharmacol. 1989, 13
(Suppl. 3), S67-S69. (b) Skidgel, R. A.; Engelbrecht, S.; J ohnson,
A. R.; Erdos, E. G. Hydrolysis of Substance P and Neurotensin
by Converting Enzyme and Neutral Endopeptidase. Peptides
1984, 5, 769-776.
(24) Purrington, S. T.; Everett, T. S.; Bumgarder, C. L. Preparation
of Esters Containing an R-CF3 Group. Tetrahedron Lett. 1984,
25, 1329-1332.
(25) Robertson, M. J .; Barnes, J . C.; Drew, G. M.; Clark, K. L.;
Marshall, F. H.; Michel, A.; Middlemiss, D.; Ross, B. C.; Scopes,
D.; Dowle, M. D. Pharmacological Profile of GR117289 in vitro:
(6) Moore, A. F.; Fulton, R. W. Angiotensin II Antagonists-Saralasin.
Drug Dev. Res. 1984, 4, 331-349.
(7) (a) Furukawa, Y.; Kishimoto, S.; Nishikawa, K. U.S. Patent
4340598, 1982. (b) Furukawa, Y.; Kishimoto, S.; Nishikawa, K.
U.S. Patent 4355040, 1982.
a
Novel, Potent and Specific Nonpeptide Angiotensin AT1
(8) Carini, D. J .; Duncia, J . V.; Aldrich, P. E.; Chiu, A. T.; J ohnson,
A. L.; Pierce, M. E.; Price, W. A.; Santella, J . B., III; Wells, G.
J .; Wexler, R. R.; Wong, P. C.; Yoo, S.; Timmermans, P. B. M.
W. M. Nonpeptide Angiotensin II Receptor Antagonists: The
Discovery of a Series of N-(Biphenylmethyl)imidazoles as Potent,
Orally Active Antihypertensives. J . Med. Chem. 1991, 34, 2525-
2547.
(9) Nahmias, C.; Strosberg, A. D. The Angiotensin AT2 Receptor:
Searching for Signal-Transduction Pathways and Physiological
Function. Trends Pharmacol. Sci. 1995, 16, 223-225.
(10) Ashton, W. T. Nonpeptide Angiotensin II Receptor Antagonists.
Exp. Opin. Invest. Drugs 1994, 3, 1105-1142.
(11) Mantlo, N. B.; Chakravarty, P. K.; Ondeyka, D. L.; Siegl, P. K.
S.; Chang, R. S.; Lotti, V. J .; Faust, K. A.; Chen, T.; Schorn, T.
W.; Sweet, C. S.; Emmert, S. E.; Patchett, A. A.; Greenlee, W. J .
Potent, Orally Active Imidazo[4,5-b]pyridine-Based Angiotensin
II Receptor Antagonists. J . Med. Chem. 1991, 34, 2919-2922.
(12) Chakravarty, P. K.; Naylor, E. M.; Chen, A.; Chang, R. S. L.;
Chen, T.; Faust, K. A.; Lotti, V.; Kivlighn, S. D.; Gable, R. A.;
Zingaro, G. J .; Schorn, T. W.; Schaffer, L. W.; Broten, T. P.; Siegl,
P. K. S.; Patchett, A. A.; Greenlee, W. J . A Highly Potent, Orally
Active Imidazo[4,5-b]pyridine Biphenylsulfonamide (MK-996;
Receptor Antagonist. Br. J . Pharmacol. 1992, 107, 1173-1180.
(26) Wong, P. C.; Price, W. A.; Chiu, A. T.; Duncia, J . V.; Carini, D.
J .; Wexler, R. R.; J ohnson, A. L.; Timmermans, P. B. M. W. M.
Nonpeptide Angiotensin II Receptor Antagonists. VIII. Charac-
terization of Functional Antagonism Displayed by DUP-753, an
Orally Active Antihypertensive Agent. J . Pharmacol. Exp. Ther.
1990, 252, 719-725.
(27) (a) Rivero, R. A.; Kevin, N. J .; Allen, E. E. New Potent
Angiotensin II Receptor Antagonists Containing Phenylthio-
phenes and Phenylfurans in Place of the Biphenyl Moiety.
Bioorg. Med. Chem. Lett. 1993, 3, 1119-1124. (b) Salimbeni, A.;
Canevotti, R.; Paleari, F.; Bonaccorsi, F.; Renzetti, A. R.; Belvisi,
L.; Bravi, G.; Scolastico, C. Nonpeptide Angiotensin II Receptor
Antagonists. Synthesis, in Vitro Activity, and Molecular Model-
ing Studies of N-[(Heterobiaryl)methyl]imidazoles. J . Med.
Chem. 1994, 37, 3928-3938.
(28) Cavalcanti, F. L.; Go´mez, L. A.; F. de Arriba, A.; Garc´ıa-Rafanell,
J .; Forn, J . UR-7198: A Novel Orally Active Non-peptide AT1
Receptor Antagonist. Presented at the VII European Meeting
on Hypertension, Milan, Italy, 1995.
(29) Wood, J . M.; Chin-Mah, S.; Schnell, C. Comparison of the Acute
Hypotensive Effects of Renin Inhibition, Converting Enzyme
Inhibition and Angiotensin II Antagonism in Rats. J . Cardiovasc.
Pharmacol. 1990, 16 (Suppl. 4), 560-564.
L-159,282):
A New AT1-Selective Angiotensin II Receptor
Antagonist. J . Med. Chem. 1994, 37, 4068-4072.
(13) J udd, D. B.; Dowle, M. D.; Middlemiss, D.; Scopes, D. I. C.; Ross,
B. C.; J ack, T. I.; Pass, M.; Tranquillini, E.; Hobson, J . E.;
Panchal, T. A.; Stuart, P. G.; Paton, J . M. S.; Hubbard, T.;
Hilditch, A.; Drew, G. M.; Robertson, M. J .; Clark, K. L.; Travers,
A.; Hunt, A. A. E.; Polley, J .; Eddershaw, P. J .; Bayliss, M. K.;
Manchee, G. R.; Donnelly, M. D.; Walker, D. G.; Richards, S. A.
Bromobenzofuran-Based Nonpeptide Antagonists of Angiotensin
II: GR138950, a Potent Antihypertensive Agent with High Oral
Bioavailability. J . Med. Chem. 1994, 37, 3108-3120.
(14) Dhanoa, D. S.; Bagley, S. W.; Chang, R. S. L.; Lotti, V. J .; Chen,
T.; Kivlighn, S. D.; Zingaro, G. J .; Siegl, P. K. S.; Patchett, A.
A.; Greenlee, W. J . Nonpeptide Angiotensin II Receptor Antago-
nists. 1. Design, Synthesis, and Biological Activity of N-Substi-
tuted Indoles and Dihydroindoles. J . Med. Chem. 1993, 36,
4230-4238.
(30) Nieto, C.; Ramis, J .; Conte, L.; Forn, J . Unpublished results.
(31) Carini, D. J .; Ardecky, R. J .; Ensinger, C. L.; Pruitt, J . R.; Wexler,
R. R.; Wong, P. C.; Huang, S.-M.; Aungst, B. J .; Timmermans,
P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antago-
nists: The discovery of DMP 581 and DMP 811. Bioorg. Med.
Chem. Lett. 1994, 4, 63-68.
(32) Breen, M. P.; Bojanowski, E. M.; Cipolle, R. J .; Dunn, W. J .;
Frank, E.; Gearien, J . E. Anticonvulsant Activity of Substituted
Benzoyl Pyridines. J . Pharm. Sci. 1973, 62, 847.
(33) Terai, M.; Takenaka, M.; Maeno, H. Inhibition of Calcium Influx
in Rabbit Aorta by Nicardipine Hydrochloride (YC-93). Biochem.
Pharmacol. 1981, 30, 375-378.
J M9508853